type 3 system Search Results


cultrex basement membrane matrix  (Trevigen)
92
Trevigen cultrex basement membrane matrix
Cultrex Basement Membrane Matrix, supplied by Trevigen, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cultrex basement membrane matrix/product/Trevigen
Average 92 stars, based on 1 article reviews
cultrex basement membrane matrix - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
basement membrane matrix bme type 3  (Trevigen)
94
Trevigen basement membrane matrix bme type 3
Basement Membrane Matrix Bme Type 3, supplied by Trevigen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/basement membrane matrix bme type 3/product/Trevigen
Average 94 stars, based on 1 article reviews
basement membrane matrix bme type 3 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
enzyme linked immunosorbent assay kits  (Elabscience Biotechnology)
93
Elabscience Biotechnology enzyme linked immunosorbent assay kits
Enzyme Linked Immunosorbent Assay Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/enzyme linked immunosorbent assay kits/product/Elabscience Biotechnology
Average 93 stars, based on 1 article reviews
enzyme linked immunosorbent assay kits - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
tnni3  (Novus Biologicals)
93
Novus Biologicals tnni3
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Tnni3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tnni3/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
tnni3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
cultrex basement membrane matrix type 3  (Trevigen)
90
Trevigen cultrex basement membrane matrix type 3
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Cultrex Basement Membrane Matrix Type 3, supplied by Trevigen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cultrex basement membrane matrix type 3/product/Trevigen
Average 90 stars, based on 1 article reviews
cultrex basement membrane matrix type 3 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse cardiac troponin i type 3 elisa kit  (Novus Biologicals)
94
Novus Biologicals mouse cardiac troponin i type 3 elisa kit
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Mouse Cardiac Troponin I Type 3 Elisa Kit, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse cardiac troponin i type 3 elisa kit/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
mouse cardiac troponin i type 3 elisa kit - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cultrex basement membrane extract  (R&D Systems)
93
R&D Systems cultrex basement membrane extract
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Cultrex Basement Membrane Extract, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cultrex basement membrane extract/product/R&D Systems
Average 93 stars, based on 1 article reviews
cultrex basement membrane extract - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
type 3  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc type 3
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Type 3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/type 3/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
type 3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
antibodies against cxcr3  (Boster Bio)
94
Boster Bio antibodies against cxcr3
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Antibodies Against Cxcr3, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against cxcr3/product/Boster Bio
Average 94 stars, based on 1 article reviews
antibodies against cxcr3 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
mouse tnni3 ctn i  (Elabscience Biotechnology)
94
Elabscience Biotechnology mouse tnni3 ctn i
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Mouse Tnni3 Ctn I, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse tnni3 ctn i/product/Elabscience Biotechnology
Average 94 stars, based on 1 article reviews
mouse tnni3 ctn i - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
troponin i type 3 cardiac  (Novus Biologicals)
93
Novus Biologicals troponin i type 3 cardiac
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Troponin I Type 3 Cardiac, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/troponin i type 3 cardiac/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
troponin i type 3 cardiac - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
hep3b cells  (R&D Systems)
93
R&D Systems hep3b cells
FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, <t>TNNI3)</t> levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)
Hep3b Cells, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hep3b cells/product/R&D Systems
Average 93 stars, based on 1 article reviews
hep3b cells - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, TNNI3) levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)

Journal: Frontiers in Molecular Medicine

Article Title: Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model

doi: 10.3389/fmmed.2024.1487526

Figure Lengend Snippet: FIGURE 3 Cardiac effects of anti-PD-L1 treatment in B16F10-GCV mice. Dot plots summarizing (A) αMHC and (B) βMHC mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (C) Ratio of βMHC/αMHC mRNA expression of B16F10- GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (D) Representative cardiac TnT western blot and (E) dot plot summarizing quantification of cardiac TnT protein expression normalised to Ponceau S staining in cardiac tissue of B16F10-GCV LVs treated with anti-PD-L1 (N = 8) or isotype Ctrl (N = 6). Uncropped full length images are presented in SFig. 6A + B. (F) The dot plots summarize circulating plasma troponin I type 3 (cardiac, TNNI3) levels from B16F10-GCV mice treated with anti-PD-L1 (N = 19) or isotype Ctrl (N = 11). Dot plots summarizing (G) Atp2a2, (H) Adcy5, (I) Adcy6 and (J) Ryr2 mRNA levels normalized to 18S RNA analysed by qRT-PCR in B16F10-GCV LVs treated with anti-PD-L1 (N = 13) or isotype Ctrl (N = 13). (K) Representative cardiac ATP2A2 western blot and (L) dot plot summarizing quantification of cardiac ATP2A2 protein expression normalized to Ponceau S staining in (Continued)

Article Snippet: Mouse troponin I type 3 cardiac (TNNI3; Novus Biologicals #NBP3-00456) levels were measured in plasma using a commercial ELISA kit following the manufacturer’s protocol.

Techniques: Quantitative RT-PCR, Expressing, Western Blot, Staining, Clinical Proteomics